SRR10842375
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.500
- PROTEIN_SECRETION+0.500
- UNFOLDED_PROTEIN_RESPONSE+0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- MTORC1_SIGNALING+0.400
- ANDROGEN_RESPONSE+0.300
- ANGIOGENESIS+0.300
- CHOLESTEROL_HOMEOSTASIS+0.300
- HYPOXIA+0.300
- MYC_TARGETS_V2+0.300
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.400
- INTERFERON_GAMMA_RESPONSE-0.400
- NOTCH_SIGNALING-0.400
- WNT_BETA_CATENIN_SIGNALING-0.400
- E2F_TARGETS-0.300
- HEDGEHOG_SIGNALING-0.300
- IL6_JAK_STAT3_SIGNALING-0.300
- INTERFERON_ALPHA_RESPONSE-0.300
- BILE_ACID_METABOLISM-0.200
- COMPLEMENT-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5088827 | — | — | 0.764 |
| 2 | ERR2278862 | — | — | 0.739 |
| 3 | SRR8518238 | — | C | 0.730 |
| 4 | TCGA-73-4670-01A-01R-1206-07 | — | cohortA4 | 0.721 |
| 5 | MNG1207 | — | — | 0.711 |
| 6 | TCGA-BH-A0HX-01A-21R-A056-07 | — | B | 0.707 |
| 7 | TCGA-P3-A6T3-01A-11R-A34R-07 | — | — | 0.707 |
| 8 | SRR8518157 | — | F | 0.692 |
| 9 | C3L-01632 | — | cohortA4 | 0.689 |
| 10 | MNG999 | — | — | 0.687 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.500 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.500 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |